Ipsen (FR:IPN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Ipsen has secured exclusive global rights to BMX-502, a promising preclinical T-cell engager developed by Biomunex, aiming to harness MAIT cells for cancer treatment. This innovative bispecific antibody targets MAIT cells and the tumor antigen GPC3, potentially offering a more effective and safer therapy for solid tumors. Ipsen will handle clinical development and commercialization, while Biomunex stands to receive up to $610 million through various payments and royalties.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Hans Mosesmann About Intel Stock
- Canaccord Pounds the Table on Archer Aviation Stock
- ‘Don’t Let the Law of Large Numbers Scare You,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
